行情

BVXV

BVXV

Biondvax制药
NASDAQ

实时行情|Nasdaq Last Sale

36.00
-2.49
-6.47%
已收盘, 16:00 08/11 EDT
开盘
37.50
昨收
38.49
最高
38.47
最低
34.00
成交量
6.08万
成交额
--
52周最高
62.00
52周最低
5.20
市值
4.09亿
市盈率(TTM)
-3.7491
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BVXV价格均价为30.00,最高价位30.00,最低价为30.00。

EPS

BVXV 新闻

更多
Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q2 Views
Following the market opening Tuesday, the Dow traded up 0.15% to 26123.80 while the NASDAQ fell 1.74% to 10210.48. The S&P also fell, dropping 0.55% to 3,137.81.
Benzinga · 07/14 15:31
The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 12:04
80 Biggest Movers From Yesterday
Gainers Equillium, Inc. (NASDAQ: EQ) shares surged 730.7% to close at $26.50 on Monday after the company disclosed that Itolizumab significantly reduced mortality in coronavirus patients, according to a clinical trial conducted in India by its partner Biocon.
Benzinga · 07/14 09:11
Mid-Afternoon Market Update: Dow Jumps 400 Points; Equillium Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 1.55% to 26,475 while the NASDAQ rose 0.72% to 10,693.37. The S&P also rose, gaining 1.03% to 3,217.92.
Benzinga · 07/13 18:31
Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Estimates
Following the market opening Monday, the Dow traded up 0.99% to 26333.97 while the NASDAQ rose 1.30% to 10,755.51. The S&P also rose, gaining 0.86% to 3,212.49.
Benzinga · 07/13 14:13
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 07/10 11:25
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 07/09 12:09
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 07/08 11:31

所属板块

生物技术和医学研究
-2.23%
制药与医学研究
-0.89%

热门股票

代码
价格
涨跌幅

BVXV 简况

BiondVax Pharmaceuticals Ltd是一家以色列的三期临床阶段生物制药公司。它正在开发M-001通用流感疫苗。M-001正在约12400名参与者中进行关键的临床疗效三期试验。M-001旨在针对所有季节性和大流行的人类流感病毒株提供多季节和多重保护。在六项完整的临床试验中,该疫苗被证明对多种流感病毒株具有安全性、良好耐受性和免疫原性。该公司的技术利用来自流感病毒蛋白的保守肽和常见肽的专有组合来激活免疫系统的能力,从而具有交叉保护和持久作用。
展开

微牛提供Biondvax Pharmaceuticals Ltd - ADR(NASDAQ-BVXV)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BVXV股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BVXV股票基本功能。